Previous studies have established that cellular Lamin A/C is lost or reduced in breast and ovarian cancer cells (Capo-chichi et al., 2011a; Capo-chi et al., 2011b; Capo-Chichi et al., 2016; Smith et al., 2018a; Smith et al., 2018b), and reduced Lamin A/C underlying nuclear envelope distortion and malleability (Smith et al., 2017), explaining the mechanism that Lamin A/C is a key determinant of paclitaxel sensitivity (Smith et al., 2021; Smith et al., 2022). Here, LMNA is linked to ovarian cancer.